Pfizer Expands Migraine Strategy With New Rimegepant Redosing Study
Pfizer Inc (PFE) announced an update on their ongoing clinical study.
4th of July Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Pfizer tests migraine pill redosing in new phase 4 trial. The study, titled “A Phase 4, Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability and Effectiveness of Redosing of Rimegepant,” aims to see if a second dose of rimegepant is safe and helpful when the first dose does not fully stop a migraine attack.
The treatment under review is rimegepant, an oral drug tablet used for acute migraine relief. The trial focuses on giving adults a first 75 mg dose and, if needed, a second 75 mg dose within 24 hours to manage pain or relapse, testing whether redosing can extend relief without adding safety concerns.
This is an interventional phase 4 study using a single treatment group, with no placebo or comparison arm. It is non-randomized and open label, meaning all participants know they are taking rimegepant, and the main goal is to assess treatment safety and tolerability rather than to prove superiority over another drug.
The trial is currently recruiting, with initial submission dated 20 May 2026, marking the formal start of regulatory tracking. The latest update on 29 June 2026 signals active study management and protocol refinement, while primary and final completion dates are not yet posted, so investors should treat timelines as early stage and subject to change.
For investors, this update reinforces Pfizer’s push to deepen its migraine franchise and defend share in an increasingly crowded acute migraine market. Positive safety and effectiveness data on redosing could support broader real‑world use, help differentiate rimegepant versus other CGRP drugs, and modestly improve sentiment on PFE, while also pressuring competitors to match flexible dosing options.
The trial remains ongoing and updated, with further details available on the ClinicalTrials portal.
To learn more about PFE’s potential, visit the Pfizer Inc drug pipeline page.
